Study | Research Studies | School of Medicine

CBD for Individuals with Mild Cognitive Impairment and at Risk for Alzheimer's Disease

Primary Objective

Our study is seeking individuals aged 55-85, who have been diagnosed with Mild Cognitive Impairment (MCI) and are at risk for Alzheimer's Disease. The goal of the study is to see whether cannabinoids (CBD) can improve MCI symptoms. Study medication is provided.

Is This Study For You?

Let's Get Started!

Description

This study plans to learn more about different types of CBD in reducing symptoms of MCI (sleep and cognitive dysfunction, anxiety, and inflammation).

Main Procedures Involved: Blood draws, questionnaires, and cognitive tests.

Duration of Participation: 24 weeks

Details

Age

55 to 85 years

Eligibility

- Must be between the ages of 55 – 85. - Participant must have a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation. - Must have an informant that will be utilized over the course of the 24 week study. - Must be interested in using CBD to help with cognitive function. - Must plan on living in the Denver metro area over the next 6 months. - Able to attend in-person visits at the study site.

Compensation

Provided

Locations

CU Anschutz non-hospital research facilities

Principal Investigator

Kent Hutchison

Resources

Study Flier

Study ID

Protocol Number: 23-0619

More information available at ClinicalTrials.gov: NCT05822362

Is this Study for You?